GLP-1 & Incretin Science

Where the Thyroid Warning Came From

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Bjerre Knudsen and colleagues reported in Endocrinology in 2010 that GLP-1 receptor agonists activate rodent thyroid C-cells, causing calcitonin release and C-cell proliferation. That finding, replicated and characterised as on-target, is the origin of the boxed warning.

Key facts

Foundational paper
Bjerre Knudsen 2010, Endocrinology
PMID
20203154
Species
Rats and mice
Observed
Calcitonin release, C-cell proliferation
Characterisation
On-target, receptor-mediated
Follow-up
Rosol 2013, Toxicol Pathol (PMID 23471186)

What C-cells are

Parafollicular cells in the thyroid that produce calcitonin, a hormone involved in calcium handling. They are a minority population and distinct from the follicular cells that make thyroid hormone, which is why medullary thyroid carcinoma, arising from C-cells, is a different disease from the far commoner papillary and follicular thyroid cancers.

What was observed

In rats and mice given GLP-1 receptor agonists, C-cells released calcitonin and proliferated. With sustained exposure this progressed to C-cell hyperplasia and, in some animals, to tumours. The 2010 Endocrinology paper established the sequence rather than merely reporting an endpoint, which is what made it persuasive.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why on-target is the important descriptor

Rosol and colleagues characterised these as on-target effects in Toxicologic Pathology in 2013. On-target means the effect proceeds through the intended receptor rather than through an unrelated interaction or a contaminant. That makes it a predictable consequence of the pharmacology in that species. It also means the effect should be expected wherever the receptor is present at sufficient density, which becomes the crux of the human question.

Why regulators acted on a rodent finding

Because a receptor-mediated proliferative effect in two species is a serious signal, and medullary thyroid carcinoma is a condition where caution is cheap relative to the consequence. The resulting boxed warning contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

The question the rodent work raises but cannot answer

Whether human C-cells behave the same way. An on-target effect depends on the target being present, and receptor expression differs between species more often than is assumed. That question was addressed directly by later work, and the answer is not what a straightforward reading of the rodent data would predict.

What this concerns

Licensed medicines assessed by regulators, and toxicology conducted under regulated conditions. Nothing supplied on this site is a GLP-1 receptor agonist, and none of this literature describes anything sold here.

Frequently asked questions

What did the rodent studies show?

GLP-1 receptor agonists activated thyroid C-cells in rats and mice, causing calcitonin release and proliferation, progressing to hyperplasia and in some animals tumours.

What does 'on-target' mean?

That the effect proceeds through the intended receptor rather than an unrelated interaction, making it a predictable consequence of the pharmacology in that species.

What does the boxed warning say?

It contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.